Lilly(US:LLY) Ge Long Hui A P P·2025-08-26 11:11Core Viewpoint - Eli Lilly's oral GLP-1 drug Orforglipron has shown positive results in Phase 3 trials, which will lead to a submission for global regulatory approval within this year [1] Company Summary - Eli Lilly's stock surged over 2% in pre-market trading following the announcement of the positive trial results for Orforglipron [1] - The drug is aimed at treating obesity, indicating a strategic focus on expanding the company's portfolio in the obesity treatment market [1] Industry Summary - The successful Phase 3 trial results for Orforglipron highlight the growing interest and investment in obesity treatment solutions within the pharmaceutical industry [1] - The anticipated regulatory submission reflects the industry's trend towards developing innovative therapies for chronic conditions like obesity [1]